Sobi to take direct responsibility for Orfadin in the US, Canada and Latin America

Swedish  Orphan Biovitrum AB (publ) (Sobi)  announced today that the company has
decided  to take direct responsibility for Orfadin® in the US, Canada, and Latin
America  by terminating the current distributorship agreement with their partner
Rare Disease Therapeutics, Inc (RDT). Financial details were not disclosed.

"Our US subsidiary is ready to consistently and safely supply Orfadin to
patients throughout the Americas, and we look forward to bringing a global
perspective to partnering with Genetic and Metabolic physicians in serving the
Tyrosinemia community in these territories," said Geoffrey McDonough, Sobi's
CEO.

The distributorship will transfer to Sobi on 1 April 2014 for the US and Canada,
and on 1 January 2015 for Latin America.

---

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com

For more information - not for publication
Media relations                      Investor relations

Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
                                     Investor Relations

T: +46 70 410 71 80                  T: +46 8 697 20 00

oskar.bosson@sobi.com                jorgen.winroth@sobi.com



[HUG#1751522]